Feasibility study of docetaxel and nedaplatin for recurrent squamous cell carcinoma of the uterine cervix
| Autor: | Yoh, Watanabe, Hidekatsu, Nakai, Tomomaro, Etoh, Kazumi, Kanemura, Isao, Tsuji, Ayako, Ishizu, Hiroshi, Hoshiai |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Adult
Dose-Response Relationship Drug Organoplatinum Compounds Uterine Cervical Neoplasms Docetaxel Leukopenia Middle Aged Antineoplastic Combined Chemotherapy Protocols Granulocyte Colony-Stimulating Factor Carcinoma Squamous Cell Feasibility Studies Humans Female Taxoids Neoplasm Recurrence Local Aged Agranulocytosis |
| Zdroj: | Anticancer research. 28(4C) |
| ISSN: | 0250-7005 |
| Popis: | To determine a new taxane plus platinum treatment regimen for squamous cell carcinoma of the uterine cervix (CSCC), a phase I feasibility study of docetaxel (DTX) plus nedaplatin (CDGP) combination therapy was conducted.Twenty consecutive patients were enrolled into the study. The starting dose of DTX/CDGP was 60 mg/m2 / 80 mg/m2, every 4 weeks for at least three courses and the dose was escalated to 70 mg/m2 / 100 mg/m2. DTX 60 mg/m2 / CDGP 100 mg/m2 was also evaluated as an extra dose level.Dose-limiting toxicity was granulocytopenia and the maximum tolerated dose was determined as 70 mg/m2 / 100 mg/m2. All 20 patients had measurable disease and a partial response was achieved in 8 (40.0%) patients.DTX/CDGP therapy appears to be a tolerable regimen for cervical squamous cell carcinoma, even in patients previously treated by cisplatin concurrent chemoradiotherapy. The recommended doses of DTX and CDGP were determined to be 60 mg/m2 and 100 mg/m2, respectively. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|